Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.

doi:10.1016/j.cllc.2021.02.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.

Clinical lung cancer - 1 Jul 2021

Shirasawa Masayuki, Yoshida Tatsuya, Takayanagi Daisuke, Shiraishi Kouya, Yagishita Shigehiro, Sekine Katsutoshi, Kanda Shintaro, Matsumoto Yuji, Masuda Ken, Shinno Yuki, Okuma Yusuke, Goto Yasushi, Horinouchi Hidehito, Hamada Akinobu, Kohno Takashi, Yamamoto Noboru, Watanabe Shun-Ichi, Ohe Yuichiro, Motoi Noriko

Abstract excerpt

BACKGROUND: The efficacy of anti-programmed death receptor 1 (PD-1) therapy in patients with large cell neuroendocrine carcinoma (LCNEC) remains unclear. We investigated the outcome of anti-PD-1 therapy and its predictive markers by evaluating the immune-related tumor microenvironment. PATIENTS: We retrospectively reviewed patients with advanced LCNEC treated with systemic chemotherapy. We also evaluated PD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Large Cell

Share to Carcinoma, Neuroendocrine

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Survival Rate

Share to Tumor Microenvironment

Source

Open in PubMed

Identifiers

PMID: 33722498
DOI: 10.1016/j.cllc.2021.02.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.PMID 33722498Read ↗

Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.Semantic proximity Read ↗

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.Semantic proximity Read ↗

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.Semantic proximity Read ↗

BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.Semantic proximity Read ↗

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.Semantic proximity Read ↗

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.Semantic proximity Read ↗

TP53 Mutation and Tumor-Infiltrating Lymphocytes as Predictors of PD-1/PD-L1 Inhibitor Efficacy in PD-L1-High Advanced NSCLC.Semantic proximity Read ↗

Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic RelevanceSemantic proximity Read ↗

Clinical implications of tumor-intrinsic mechanisms regulating PD-L1Semantic proximity Read ↗

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung CancerSemantic proximity Read ↗

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.